{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": -0.69930005, "regularMarketPrice": 2.84, "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "exchange": "STU", "shortName": "VBI Vaccines Inc.", "longName": "VBI Vaccines Inc.", "messageBoardId": "finmb_289036322", "exchangeTimezoneName": "Europe/Berlin", "marketState": "REGULAR", "firstTradeDateMilliseconds": 1462946400000, "priceHint": 4, "regularMarketChange": -0.01999998, "regularMarketTime": 1683871466, "regularMarketDayHigh": 2.84, "regularMarketDayRange": "2.84 - 2.84", "regularMarketDayLow": 2.84, "regularMarketVolume": 0, "regularMarketPreviousClose": 2.86, "bid": 2.76, "ask": 2.98, "fullExchangeName": "Stuttgart", "financialCurrency": "USD", "regularMarketOpen": 2.84, "averageDailyVolume3Month": 167, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 2.7359998, "fiftyTwoWeekLowChangePercent": 26.30769, "fiftyTwoWeekRange": "0.104 - 4.35", "fiftyTwoWeekHighChange": -1.51, "fiftyTwoWeekHighChangePercent": -0.34712645, "fiftyTwoWeekLow": 0.104, "fiftyTwoWeekHigh": 4.35, "earningsTimestamp": 1678708801, "earningsTimestampStart": 1691411400, "earningsTimestampEnd": 1691757000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -14.52, "sharesOutstanding": 8608540, "bookValue": 7.453, "fiftyDayAverage": 1.408636, "fiftyDayAverageChange": 1.4313639, "fiftyDayAverageChangePercent": 1.0161347, "twoHundredDayAverage": 0.838612, "twoHundredDayAverageChange": 2.0013878, "twoHundredDayAverageChangePercent": 2.386548, "marketCap": 24448252, "priceToBook": 0.38105458, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "symbol": "LO9A.SG"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "160 Second Street", "address2": "Floor 3", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 830 3031", "website": "https://www.vbivaccines.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 190, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jeffery R. Baxter F.C.M.A., FCMA", "age": 61, "title": "Pres, CEO & Director", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": {"raw": 908059, "fmt": "908.06k", "longFmt": "908,059"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David Evander Anderson", "age": 52, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 534250, "fmt": "534.25k", "longFmt": "534,250"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Francisco  Diaz-Mitoma FRCPC, M.D., Ph.D.", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1955, "fiscalYear": 2022, "totalPay": {"raw": 544517, "fmt": "544.52k", "longFmt": "544,517"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nell  Beattie", "age": 34, "title": "CFO, Head of Corp. Devel. & Director", "yearBorn": 1988, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Nicole  Anderson", "title": "Director of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Athena  Kartsaklis", "age": 57, "title": "Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Avi  Mazaltov", "age": 60, "title": "Global Head of Manufacturing & GM of SciVac", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Misha  Nossov", "title": "Sr. VP of Global Commercial Supply Strategy & Head of Europe", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. T. Adam Buckley", "age": 46, "title": "Sr. VP of Bus. Devel.", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John Robert Dillman", "age": 54, "title": "Chief Commercial Officer", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 2, "overallRisk": 7, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}